CER-001

CER-001 is a recombinant high-density lipoprotein (HDL) mimetic that has orphan drug status.

[1] It is in early-stage clinical trials for the potential treatment of hypoalphalipoproteinaemia,[2] acute coronary syndrome (ACS),[3] acute kidney injury (AKI),[4][5][6] atherosclerosis[7] and lecithin cholesterol acyltransferase (LCAT) deficiency.

[8] CER-001 is also under investigation as possible agent for treating hyperinflammatory states based on lipid profile alterations due to COVID-19.

[9][10] CER-001 is an artificially synthesized mimetic of recombinant human apolipoprotein AI (ApoA1), the main structural protein of natural HDL, together with two phospholipids, which are: sphingomyelin and dipalmitoyl-phosphatidylglycerol.

[15] It did not appear to affect clinical chemistry, hematology or coagulation parameters and is considered safe.